https://www.selleckchem.com/pr....oducts/cilofexor-gs-
Two trials could change clinical practice for certain subtypes of renal cell carcinoma (RCC). In one, the combination of lenvatinib and pembrolizumab was superior to sunitinib and to lenvatinib plus everolimus in clear-cell RCC. In the other, cabozantinib was more effective than sunitinib in papillary RCC.Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-b
Like
Comment
Share
